Nef Inhibits Glucose Uptake in Adipocytes and Contributes to Insulin Resistance in Human Immunodeficiency Virus Type I InfectionCHENEY, Laura; HOU, June C; MORRISON, Sidonie et al.The Journal of infectious diseases. 2011, Vol 203, Num 12, pp 1824-1831, issn 0022-1899, 8 p.Article

Targeting pandemic influenza: a primer on influenza antivirals and drug resistanceMOSS, Ronald B; DAVEY, Richard T; STEIGBIGEL, Roy T et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 6, pp 1086-1093, issn 0305-7453, 8 p.Article

Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophyMYNARCIK, Dennis C; MCNURLAN, Margaret A; STEIGBIGEL, Roy T et al.Journal of acquired immune deficiency syndromes (1999). 2000, Vol 25, Num 4, pp 312-321, issn 1525-4135Article

Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment- Experienced Patients with Drug- Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III TrialsSTEIGBIGEL, Roy T; COOPER, David A; YENI, Patrick et al.Clinical infectious diseases. 2010, Vol 50, Num 4, pp 605-612, issn 1058-4838, 8 p.Article

Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot studyGELATO, Marie C; MYNARCIK, Dennis C; QUICK, Joyce L et al.Journal of acquired immune deficiency syndromes (1999). 2002, Vol 31, Num 2, pp 163-170, issn 1525-4135, 8 p.Article

Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionCOOPER, David A; STEIGBIGEL, Roy T; SCHECHTER, Mauro et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 355-365, issn 0028-4793, 11 p.Article

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trialsERON, Joseph J; COOPER, David A; LOUTFY, Mona R et al.Lancet. Infectious diseases (print). 2013, Vol 13, Num 7, pp 587-596, issn 1473-3099, 10 p.Article

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity : sub-analysis from RESISTRAFFI, Francois; BATTEGAY, Manuel; RUSCONI, Stefano et al.AIDS (London). 2007, Vol 21, Num 14, pp 1977-1980, issn 0269-9370, 4 p.Article

A Phase II Study of DAS181, a Novel Host Directed Antiviral for the Treatment of Influenza InfectionMOSS, Ronald B; HANSEN, Carrie; SANDERS, Rebecca L et al.The Journal of infectious diseases. 2012, Vol 206, Num 12, pp 1844-1851, issn 0022-1899, 8 p.Article

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMARKOWITZ, Martin; MORALES-RAMIREZ, Javier O; WENNING, Larissa et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 5, pp 509-515, issn 1525-4135, 7 p.Article

Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionSTEIGBIGEL, Roy T; COOPER, David A; KATLAMA, Christine et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 339-354, issn 0028-4793, 16 p.Article

Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionHIRSCH, Martin S; STEIGBIGEL, Roy T; LEAVITT, Randi Y et al.Clinical infectious diseases. 2003, Vol 37, Num 8, pp 1119-1124, issn 1058-4838, 6 p.Article